---
title: "Evolus (EOLS) Receives a Buy from Mizuho Securities"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289108379.md"
description: "Mizuho Securities analyst Uy Ear reiterated a Buy rating on Evolus (EOLS) with a $15.00 price target. This aligns with the stock's Strong Buy consensus and an average price target of $14.50. The analyst covers the Healthcare sector, including Alkermes and Sarepta Therapeutics."
datetime: "2026-06-08T20:55:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289108379.md)
  - [en](https://longbridge.com/en/news/289108379.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289108379.md)
generator: "portal-rs"
---

# Evolus (EOLS) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Evolus today and set a price target of $15.00.

### Introducing TipRanks MCP for Agents

-   Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
-   Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Ear covers the Healthcare sector, focusing on stocks such as Alkermes, Sarepta Therapeutics, and Relmada Therapeutics. According to TipRanks, Ear has an average return of 0.1% and a 37.72% success rate on recommended stocks. 

Evolus has an analyst consensus of Strong Buy, with a price target consensus of $14.50.

### Related Stocks

- [EOLS.US](https://longbridge.com/en/quote/EOLS.US.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)
- [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md)
- [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md)
- [RLMD.US](https://longbridge.com/en/quote/RLMD.US.md)

## Related News & Research

- [EOLS: Q2 revenue up 21%, positive EBITDA, raised outlook, and expanded global portfolio for sustained growth](https://longbridge.com/en/news/295022678.md)
- [US families, healthcare providers under strain after Trump crackdown on Haitian immigrants](https://longbridge.com/en/news/296335867.md)
- [Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position](https://longbridge.com/en/news/296384188.md)
- [How Cognizant’s AI-Powered Benchling Deployment at Kyowa Kirin (CTSH) Has Changed Its Investment Story](https://longbridge.com/en/news/296072336.md)
- [Lowe’s Earns Buy Rating as Strong Earnings and Cash Generation Offset Lower-End Guidance](https://longbridge.com/en/news/296383656.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**